Brain and Spine Metastasis

Brain and Spine Metastasis

32 items identified
A Study of SEA-CD40 Given with Other Drugs in Cancers (Melanoma)
A window of opportunity study of Patritumab Deruxtecan in patients with brain metastases
ABBV-400 for Advanced Solid Tumors
ALKOVE-1 (Non-Small Cell Lung Cancer)
Alliance-A031704/PDIGREE (Renal Cell Cancer)
AMG 509 in patients with mCRPC (Prostate Cancer)
AMG 510 in Advanced Solid Tumors With KRAS p.G12C Mutation
ARC-21 (Gastrointestinal Cancer)
Chemotherapy With or Without 9-ING-41 for Pancreatic Cancer (Actuate 1801)
Circulating Biomarkers for Immunotherapy Resistance in Liver Cancer
COMPOSE Study (Neuroendocrine Tumors)
DKN-01 in Combination with Tislelizumab ± Chemotherapy in Patients with Gastric Cancer
Domvanalimab and zimberelimab versus nivolumab in gastroesophageal cancer (STAR-221)
FEATURES OF PRIMARY AND ADAPTIVE IMMUNOTHERAPY RESISTANCE IN MICROSATELLITE INSTABLE CANCERS
IDEAYA: (Melanoma with GNAQ/11 Mutations or PRKC Fusions)
Lyell LYL845 (Solid Tumors)
Magnetic Resonance Imaging (MRI) for Assessing Spinal Metastases
Merck U03B: Targeted combination therapies for second line ccRCC patients (Renal Cell Cancer)
Merck-U02-Substudy 02A_PD-1 Refractory Melanoma
MOUNTAINEER-03 (Colorectal Cancer)
MRI following Stereotactic Radiosurgery for Brain Metastases
Pembrolizumab plus lenvatinib and belzutifan for specified solid tumors
Propella: Intramuscular abiraterone decanoate for metastatic prostate cancer
PT-112 in mCRPC (Prostate Cancer)
SRS and Olaparaib followed by Durvalumab in Breast Cancer with Brain Metastases
Stellar-002: XL-092 (Kidney, Bladder, and Prostate Cancer)
Synthekine STK-012 (Solid Tumors)
TBCRC048: Metastatic Breast Cancer, BRCA Gene Mutation
The Safety and Efficacy of Targeted Therapies in Metastatic Colorectal Cancer (Intrinsic)
Tyra SURF-301: Phase 1/2 study for patients with urothelial carcinoma and an FGFR3 alteration
ViSPad Supportive Care Study for Brain Tumor Patients
Zion (Solid Tumors)